ANL (Adlai Nortye) Median PS Value: $0.00 (As of Jun. 27, 2026)


What is Adlai Nortye Median PS Value?

Adlai Nortye ANL -1.57% Median PS Value is $0.00 as of Jun. 27, 2026. The stock has 7 warning signs investors should review. Among 276 Biotechnology companies, Adlai Nortye ranks worse than 362318.48% on this metric.

This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Adlai Nortye's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.156. Adlai Nortye's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is $0.00.

As of today (2026-06-27), Adlai Nortye's share price is $10.00. Adlai Nortye's Median PS Value is $0.00. Therefore, Adlai Nortye's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Adlai Nortye's Median PS Value or its related term are showing as below:

ANL's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.62
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Adlai Nortye  (NAS:ANL) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Adlai Nortye's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=10.00/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Adlai Nortye Median PS Value Related Terms


Adlai Nortye Median PS Value Historical Data

* Premium members only.

The historical data trend for Adlai Nortye's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adlai Nortye Median PS Value Chart

Adlai Nortye Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Median PS Value
0.00 0.00 0.00 0.00 0.00

Adlai Nortye Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Median PS Value Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

ANL vs PHAT, AURA, RLMD: Median PS Value Comparison

For the Biotechnology subindustry, Adlai Nortye's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adlai Nortye Price-to-Median-PS-Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adlai Nortye's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Adlai Nortye's Price-to-Median-PS-Value falls into.



Adlai Nortye Median PS Value Calculation

Adlai Nortye's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=0.156*0
=0.00

10-Year Median PS Ratio is 0.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Adlai Nortye's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.156.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Median PS Value →
What does a Median PS Value of $0.00 mean?
Adlai Nortye (ANL) has a Median PS Value of $0.00 as of Jun. 27, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Adlai Nortye and its competitors. According to the industry distribution chart, Adlai Nortye ranks #999999 out of 276 companies in the Biotechnology industry.
Is Adlai Nortye's Median PS Value too high?
Adlai Nortye's current Median PS Value is $0.00. Based on the distribution chart, Adlai Nortye ranks #999999 out of 276 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Adlai Nortye's Median PS Value compare to PHAT and AURA?
According to the Biotechnology industry distribution chart, Adlai Nortye ranks #999999 out of 276 companies for Median PS Value. This places Adlai Nortye in the lower half of its industry. The industry median Median PS Value is 0.62. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.62, based on 276 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Adlai Nortye and its competitors. For the Biotechnology industry, the median Median PS Value is 0.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adlai Nortye's current Median PS Value is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adlai Nortye stock overvalued right now?
Adlai Nortye (ANL) has a current Median PS Value of $0.00. The current Median PS Value is $0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Adlai Nortye (ANL), the current Median PS Value is $0.00 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adlai Nortye Business Description

Other Exchanges N2U0:Germany
Address 685 US Highway 1, New Jersey Biotechnology Development Center, 2nd Floor, North Brunswick, NJ, USA, 08902
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.